Post-Crisis, Switzerland Likely To ‘Repatriate’ BioPharm Manufacturing

Switzerland’s booming, diversified biopharma ecosystem will emerge even stronger and interactive in the post-COVID-19, supported by increased domestic manufacturing capacity built in part to avoid globalization pitfalls laid bare by the pandemic, according to Michael Altorfer who heads the Swiss Biotech Association.

Altorfer told Scrip that the Swiss life sciences industry – which currently generates 40% of Switzerland’s exports - will also reap benefits in the post-pandemic world due to the country’s highly qualified workforce, growing application of artificial intelligence